patient subgroup...
non invasive oxygen
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatory therapies - versus potential COVID-19 treatments - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 0.96 [0.86, 1.07]< 1 35% 9 studies (8/1) 76.9 % moderate serious moderate crucial - death or transfer to ICU 0.83 [0.35, 1.95]< 1 0% 1 study (1/-) 66.5 % NA not evaluable crucial - deaths 0.81 [0.69, 0.94]< 1 63% 18 studies (12/6) 99.7 % low critical high crucial - deaths (time to event analysis only) 0.46 [0.21, 1.03]< 1 83% 4 studies (2/2) 97.1 % low not evaluable high crucial - clinical deterioration 0.23 [0.05, 1.03]< 1 81% 6 studies (4/2) 97.3 % low serious high important - clinical improvement 11.50 [2.57, 51.44]> 1 0% 2 studies (1/1) 99.9 % low not evaluable high important - clinical improvement (14-day) 10.27 [1.17, 90.18]> 1 0% 1 study (1/-) 98.2 % NA not evaluable important - clinical improvement (28-day) 3.52 [1.28, 9.72]> 1 0% 2 studies (1/1) 99.2 % NA not evaluable important - clinical improvement (7-day) 3.24 [1.27, 8.30]> 1 32% 2 studies (2/-) 99.3 % high not evaluable low important - death or ventilation 0.94 [0.78, 1.15]< 1 70% 2 studies (2/-) 71.9 % some concern not evaluable moderate important - hospital discharge 1.52 [0.92, 2.52]> 1 81% 4 studies (2/2) 95.0 % low not evaluable high important - mechanical ventilation 0.88 [0.72, 1.07]< 1 55% 7 studies (5/2) 90.3 % low serious high important - radiologic improvement (14-day) 2.87 [1.56, 5.28]> 1 0% 1 study (1/-) 100.0 % NA not evaluable important - viral clearance 1.71 [0.80, 3.64]> 1 0% 1 study (1/-) 91.7 % NA not evaluable important - viral clearance by day 7 1.71 [0.80, 3.64]> 1 0% 1 study (1/-) 91.7 % NA not evaluable important - ICU admission 1.00 [0.87, 1.16]< 1 0% 4 studies (3/1) 48.0 % NA not evaluable non important - recovery 3.46 [1.05, 11.35]> 1 0% 1 study (1/-) 97.9 % NA not evaluable non important - safety endpoints 00 serious adverse events 0.19 [0.04, 0.84]< 1 0% 3 studies (3/-) 98.6 % some concern not evaluable moderate important - adverse events 1.24 [0.77, 2.00]< 1 0% 6 studies (6/-) 19.2 % low not evaluable high non important - cardiovascular or renal events 1.87 [1.25, 2.80]< 1 0% 1 study (-/1) 0.1 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.